Related MeSH Hierarchy (5)
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Digestive System Neoplasms » Gastrointestinal Neoplasms » Intestinal Neoplasms » Colorectal Neoplasms » Colonic Neoplasms
Diseases [C] » Digestive System Diseases [C06] » Digestive System Neoplasms » Gastrointestinal Neoplasms » Intestinal Neoplasms » Colorectal Neoplasms » Colonic Neoplasms
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Gastrointestinal Neoplasms » Intestinal Neoplasms » Colorectal Neoplasms » Colonic Neoplasms
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Intestinal Diseases » Colonic Diseases » Colorectal Neoplasms » Colonic Neoplasms
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Intestinal Diseases » Intestinal Neoplasms » Colorectal Neoplasms » Colonic Neoplasms
Hierarchy View
Subtype Terms (2)
Sigmoid Neoplasms
4 drugs (2 approved, 2 experimental)
Approved Indicated Drugs (4)
Phase 4 Indicated Drugs (45)
Phase 3 Indicated Drugs (49)
Phase 2 Indicated Drugs (123)
ferric derisomaltose (Monoferric)
human fecal microbiota (Reybota)
immune globulin (human) (Gamastan)
Phase 1 Indicated Drugs (87)
allogeneic natural killer cells
autologous dendritic cells loaded with autologous tumor lysate
Other Experimental Indicated Drugs (42)
Organization Involved with Phase 4 Indications (36)
Badalona Hospital Germans Trias i Pujol
Clinica Universidad de Navarra
Complejo Hospitalario La Mancha Centro
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Organization Involved with Phase 3 Indications (111)
Assistance Publique - Hôpitaux de Paris
Australian and New Zealand College of Anaesthetists
Austrian Breast and Colorectal Cancer Group
Cancer and Leukemia Group B (CALGB)
Cantonal Hospital of St. Gallen
Case Western Reserve University
Central European Society for Anticancer Drug Research (CESAR)
Centro Oncologico de Excelencia
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
European Organisation for Research and Treatment of Cancer
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Groupe Regional d'Etudes du Cancer Colorectal
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Hellenic Oncology Research Group
Huazhong University of Science and Technology
Innovatiefonds Zorgverzekeraars
Nanjing NingQi Medicine Science and Technology Co., Ltd.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute on Aging (NIA)
North Central Cancer Treatment Group
Northern California Cancer Center
Royal Marsden Hospital NHS Trust
Stichting Geriatrische Oncologie Nederland
Stichting voor Patienten met Kanker aan het Spijsverteringskanaal
Swiss Group for Clinical Cancer Research
Organization Involved with Phase 2 Indications (119)
Academic and Community Cancer Research United
Biocompatibles International plc
Chao Family Comprehensive Cancer Center
City of Hope National Medical Center
Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano
Guangdong Provincial Hospital of Traditional Chinese Medicine
Heilongjiang University of Traditional Chinese Medicine
Icahn School of Medicine at Mount Sinai
Istituto Oncologico Veneto IRCCS
Katholieke Universiteit Leuven
Mt. Sinai Medical Center, Miami
National Comprehensive Cancer Network
National Institutes of Health (NIH)
People's Liberation Army of China
State University of New York, Buffalo
Organization Involved with Phase 1 Indications (38)
Organization Involved with Other Experimental Indications (32)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.